Our previous study reported that Lrp2 ASO reduced hypercholesterolemia-induced atherosclerosis in LDL receptor −/− mice.7 Therefore, subcutaneous injection of Lrp2 ASO (6 mg/kg/week) to one group of PTC-LRP2 +/+ littermates was used as a positive control for this atherosclerosis study. The gene discussed is LDLR; the disease is Hypercholesterolemia.